Cargando…

Pes Anserine Bursitis in Symptomatic Osteoarthritis Patients: A Mesotherapy Treatment Study

Background: Pes anserine bursitis strongly affects quality of life in patients with osteoarthritis. Treatment includes nonsteroidal anti-inflammatory drugs (NSAIDs), physiotherapy, and injections of corticosteroid, with highly variable responses; recovery can take 10 days to 36 months. Mesotherapy i...

Descripción completa

Detalles Bibliográficos
Autores principales: Saggini, Raoul, Di Stefano, Alexandra, Dodaj, Ira, Scarcello, Laura, Bellomo, Rosa Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522948/
https://www.ncbi.nlm.nih.gov/pubmed/26083769
http://dx.doi.org/10.1089/acm.2015.0007
_version_ 1782384014478278656
author Saggini, Raoul
Di Stefano, Alexandra
Dodaj, Ira
Scarcello, Laura
Bellomo, Rosa Grazia
author_facet Saggini, Raoul
Di Stefano, Alexandra
Dodaj, Ira
Scarcello, Laura
Bellomo, Rosa Grazia
author_sort Saggini, Raoul
collection PubMed
description Background: Pes anserine bursitis strongly affects quality of life in patients with osteoarthritis. Treatment includes nonsteroidal anti-inflammatory drugs (NSAIDs), physiotherapy, and injections of corticosteroid, with highly variable responses; recovery can take 10 days to 36 months. Mesotherapy is a minimally invasive technique consisting of subcutaneous injections of bioactive substances. The goal is to modulate the pharmacokinetics of the injected substance and prolong the effects at a local level. Objective: To evaluate the effects of mesotherapy with diclofenac for anserine bursitis associated with knee osteoarthritis. Methods: One hundred and seventeen patients with anserine bursitis associated with grade II Kellgren-Lawrence knee osteoarthritis, assessed by clinical, radiographic, and ultrasonographic examination, were evaluated and treated. They were randomly divided into two groups (A, mesotherapy; B, control). Group A completed nine sessions of mesotherapy with sodium diclofenac (25 mg/1 mL; Akis®, IBSA, Lugano, Switzerland), 1 mL for each session, three times per week. Group B received 21 oral administrations of sodium diclofenac (50 mg; Voltaren®, Novartis, Parsippany, NJ), once a day for 3 weeks. Primary outcome measures were pain intensity assessed by visual analogue scale (VAS), along with ability to perform activities of daily living, ability to participate in sports, level of pain, symptoms, and quality of life, as assessed by the Knee injury and Osteoarthritis Outcome Score. These measures were performed before and after the treatment period and at 30 and 90 days' follow up. Results: In both groups pain level decreased significantly after the treatment period. Ultrasonography showed a reduction of the hypoechoic area related to anserine bursitis only in group A. Conclusion: Administration of conventional NSAIDs (diclofenac) by mesotherapy is effective in managing anserine bursitis in knee osteoarthritis in the short term and mid-term. These observations could be of interest for efforts to reduce the adverse effects of oral administration of anti-inflammatory drugs.
format Online
Article
Text
id pubmed-4522948
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Mary Ann Liebert, Inc.
record_format MEDLINE/PubMed
spelling pubmed-45229482015-09-23 Pes Anserine Bursitis in Symptomatic Osteoarthritis Patients: A Mesotherapy Treatment Study Saggini, Raoul Di Stefano, Alexandra Dodaj, Ira Scarcello, Laura Bellomo, Rosa Grazia J Altern Complement Med Original Articles Background: Pes anserine bursitis strongly affects quality of life in patients with osteoarthritis. Treatment includes nonsteroidal anti-inflammatory drugs (NSAIDs), physiotherapy, and injections of corticosteroid, with highly variable responses; recovery can take 10 days to 36 months. Mesotherapy is a minimally invasive technique consisting of subcutaneous injections of bioactive substances. The goal is to modulate the pharmacokinetics of the injected substance and prolong the effects at a local level. Objective: To evaluate the effects of mesotherapy with diclofenac for anserine bursitis associated with knee osteoarthritis. Methods: One hundred and seventeen patients with anserine bursitis associated with grade II Kellgren-Lawrence knee osteoarthritis, assessed by clinical, radiographic, and ultrasonographic examination, were evaluated and treated. They were randomly divided into two groups (A, mesotherapy; B, control). Group A completed nine sessions of mesotherapy with sodium diclofenac (25 mg/1 mL; Akis®, IBSA, Lugano, Switzerland), 1 mL for each session, three times per week. Group B received 21 oral administrations of sodium diclofenac (50 mg; Voltaren®, Novartis, Parsippany, NJ), once a day for 3 weeks. Primary outcome measures were pain intensity assessed by visual analogue scale (VAS), along with ability to perform activities of daily living, ability to participate in sports, level of pain, symptoms, and quality of life, as assessed by the Knee injury and Osteoarthritis Outcome Score. These measures were performed before and after the treatment period and at 30 and 90 days' follow up. Results: In both groups pain level decreased significantly after the treatment period. Ultrasonography showed a reduction of the hypoechoic area related to anserine bursitis only in group A. Conclusion: Administration of conventional NSAIDs (diclofenac) by mesotherapy is effective in managing anserine bursitis in knee osteoarthritis in the short term and mid-term. These observations could be of interest for efforts to reduce the adverse effects of oral administration of anti-inflammatory drugs. Mary Ann Liebert, Inc. 2015-08-01 /pmc/articles/PMC4522948/ /pubmed/26083769 http://dx.doi.org/10.1089/acm.2015.0007 Text en © Saggini et al., 2015; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Articles
Saggini, Raoul
Di Stefano, Alexandra
Dodaj, Ira
Scarcello, Laura
Bellomo, Rosa Grazia
Pes Anserine Bursitis in Symptomatic Osteoarthritis Patients: A Mesotherapy Treatment Study
title Pes Anserine Bursitis in Symptomatic Osteoarthritis Patients: A Mesotherapy Treatment Study
title_full Pes Anserine Bursitis in Symptomatic Osteoarthritis Patients: A Mesotherapy Treatment Study
title_fullStr Pes Anserine Bursitis in Symptomatic Osteoarthritis Patients: A Mesotherapy Treatment Study
title_full_unstemmed Pes Anserine Bursitis in Symptomatic Osteoarthritis Patients: A Mesotherapy Treatment Study
title_short Pes Anserine Bursitis in Symptomatic Osteoarthritis Patients: A Mesotherapy Treatment Study
title_sort pes anserine bursitis in symptomatic osteoarthritis patients: a mesotherapy treatment study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522948/
https://www.ncbi.nlm.nih.gov/pubmed/26083769
http://dx.doi.org/10.1089/acm.2015.0007
work_keys_str_mv AT sagginiraoul pesanserinebursitisinsymptomaticosteoarthritispatientsamesotherapytreatmentstudy
AT distefanoalexandra pesanserinebursitisinsymptomaticosteoarthritispatientsamesotherapytreatmentstudy
AT dodajira pesanserinebursitisinsymptomaticosteoarthritispatientsamesotherapytreatmentstudy
AT scarcellolaura pesanserinebursitisinsymptomaticosteoarthritispatientsamesotherapytreatmentstudy
AT bellomorosagrazia pesanserinebursitisinsymptomaticosteoarthritispatientsamesotherapytreatmentstudy